Compare BTT & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTT | AMPH |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2011 | 2005 |
| Metric | BTT | AMPH |
|---|---|---|
| Price | $22.59 | $29.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.50 |
| AVG Volume (30 Days) | 119.5K | ★ 407.8K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $3.81 |
| Revenue Next Year | N/A | $4.91 |
| P/E Ratio | ★ N/A | $17.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.30 | $16.65 |
| 52 Week High | $23.24 | $31.00 |
| Indicator | BTT | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 68.14 |
| Support Level | $22.44 | $27.24 |
| Resistance Level | $22.72 | $29.35 |
| Average True Range (ATR) | 0.18 | 1.11 |
| MACD | 0.06 | 0.23 |
| Stochastic Oscillator | 74.06 | 70.53 |
Blackrock Municipal 2030 Target Term Trust is a United States-based fixed-term, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to return $25.00 per common share to common shareholders at maturity. The Fund invests the majority of its managed assets in investment-grade municipal securities, the interest of which is exempt from regular federal income tax, and derivatives that provide investment exposure to such securities or to one or more market risk factors associated with such securities.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.